Aker BioMarine files for Patent Reexamination in the U.S. against Neptune Patent

Aker BioMarine has today filed with the United States Patent and Trademark
Office ("USPTO") a request for reexamination of all claims in Neptune's
recently-issued U.S. Patent Number 8,030,348. Aker BioMarine shows in its
request that extractions of krill performed before Neptune's purported invention
produced oils containing these phospholipids, although the USPTO was not
previously informed of these facts, was not provided with copies of the relevant
publications, and was not informed of proceedings in the European patent office
in which Neptune's related European patent was ruled invalid.

"We regard this as another frivolous lawsuit from Neptune, says Hallvard Muri,
CEO of Aker BioMarine. "This patent grant is the result of mistakes made by both
the USPTO and Neptune. Contrary to Neptune's patent claims, Neptune did not
invent a phospholipid composition containing the omega-3 fatty acids EPA and
DHA", stated Hallvard Muri. "The fact is that these phospholipids occur
naturally in krill and a significant amount of prior art was not disclosed in
the Neptune application. Before the patent was granted we even sent Neptune a
copy of crucial and unconsidered prior art, but despite this they chose not to
withdraw the patent application from issue", continues Muri.

Aker BioMarine also retained an expert to repeat the experiments that Neptune
conducted and relied on to convince the U.S patent office to issue the patent.
Aker BioMarine shows in its request that those experiments, when properly
conducted and analyzed, confirm that prior extraction methods produced a krill
oil extract containing the claimed phospholipid. These facts and the prior
publications are discussed in detail in the request for reexamination, which
asks the patent office to declare the recently-issued claims to be unpatentable.

We are aware of reports that Neptune has filed a complaint against Aker
BioMarine and other entities claiming infringement of the '348 patent.  As
discussed above and in its request for reexamination, Aker BioMarine believes
that any such claims are baseless and that the '348 patent is invalid.  Aker
BioMarine will defend itself and its product vigorously against such
infringement allegations.

For further information, please contact
Matts Johansen, EVP Sales and Marketing, Aker BioMarine +47 916 30 120
Hallvard Muri, CEO, Aker BioMarine  +47 24 13 00 00

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.


[HUG#1552117]